NYSEARCA:AMPE - NYSE Arca - US03209T3077 - Common Stock - Currency: USD
Taking everything into account, AMPE scores 2 out of 10 in our fundamental rating. AMPE was compared to 198 industry peers in the Pharmaceuticals industry. AMPE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AMPE has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -150.51% | ||
ROE | -256.93% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -63.84 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.41 | ||
Quick Ratio | 2.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NYSEARCA:AMPE (4/12/2024, 8:04:00 PM)
0.62
-0.09 (-12.91%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.15 | ||
P/tB | 0.15 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -150.51% | ||
ROE | -256.93% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.41 | ||
Quick Ratio | 2.32 | ||
Altman-Z | -63.84 |